COPD as a Lung Disease with Systemic Consequences – Clinical Impact, Mechanisms, and Potential for Early Intervention

REFERENCES

• Pauwels R A, Buist A S, Calverley P M, Jenkins C R, Hurd S S, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001; 163: 1256–1276
   PubMedGoogle Scholar
• Murray C JL, Lopez A D. Alternative projections of mortality and disability by cause 1990–2020: Global burden of disease study. Lancet 1997; 349: 1498–1504
   PubMed Web of Science ®Google Scholar
• Lopez A D, Shibuya K, Rao C, Mathers C D, Hansell A L, Held L S, Schmid V, Buist S. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006; 27: 397–412
   PubMed Web of Science ®Google Scholar
• Mapel D W, Hurley J S, Frost F J, Petersen H V, Picchi M A, Coultas D B. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med 2000; 160: 2653–2658
   PubMed Web of Science ®Google Scholar
• Sorlie P D, Kannel W B, O'Connor G. Mortality associated with respiratory function and symptoms in advanced age. The Framingham Study. Am Rev Respir Dis 1989; 140: 379–384
   PubMed Web of Science ®Google Scholar
• Sin D D, Wu L, Man S F. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005; 127: 1952–1959
   PubMed Web of Science ®Google Scholar
• Mannino D M, Aguayo S M, Petty T L, Redd S C. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003; 163: 1475–1480
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Revill S M, Webb K A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 770–777
   PubMed Web of Science ®Google Scholar
• Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 1996; 153: 976–980
   PubMed Web of Science ®Google Scholar
• Engelen M P, Schols A M, Lamers R J, Wouters E F. Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease. Clin Nutr 1999; 18: 275–280
   PubMed Web of Science ®Google Scholar
• Antonelli Incalzi R, Fuso L, De Rosa M, Forestiere F, Rapiti E, Nardecchia B, Pistelli R. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 2794–2800
   PubMed Web of Science ®Google Scholar
• Marquis K, Maltais F, Duguay V, Bezeau A M, LeBlanc P, Jobin J, Poirier P. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005; 25: 226–232
   PubMedGoogle Scholar
• Mannino D M, Gagnon R C, Petty T L, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000; 160: 1683–1689
   PubMed Web of Science ®Google Scholar
• Sin D D, Man J P, Man S F. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003; 114: 10–14
   PubMed Web of Science ®Google Scholar
• Bolton C E, Ionescu A A, Shiels K M, Pettit R J, Edwards P H, Stone M D, Nixon L S, Evans W D, Griffiths T L, Shale D J. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 1286–1293
   PubMed Web of Science ®Google Scholar
• Similowski T, Agusti A, MacNee W, Schönhofer B. The potential impact of anaemia of chronic disease in COPD. Eur Respir J 2006; 27: 390–396
   PubMed Web of Science ®Google Scholar
• Cote C, Zilberberg M D, Mody S H, Dordelly L J, Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 2007; 29: 923–929
   PubMed Web of Science ®Google Scholar
• Wagena E J, Arrindell W A, Wouters E F, van Schayck C P. Are patients with COPD psychologically distressed?. Eur Respir J 2005; 26: 242–248
   PubMed Web of Science ®Google Scholar
• Sin D D, Anthonisen N R, Soriano J B, Agusti A G. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245–1257
   PubMed Web of Science ®Google Scholar
• Barnes P J. Chronic obstructive pulmonary disease (review article). N Engl J Med 2000; 343: 269–280
   PubMed Web of Science ®Google Scholar
• Sevenoaks M J, Stockley R A. Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity—a common inflammatory phenotype?. Respir Res 2006; 7: 70
   PubMed Web of Science ®Google Scholar
• Di Francia M, Barbier D, Mege J L, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 150: 1453–1455, (5 Pt 1)
   PubMed Web of Science ®Google Scholar
• Schols A MWJ, Buurman W A, Staal van den Brekel A J, Dentener M A, Wouters E F. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax 1996; 51: 819–824
   PubMed Web of Science ®Google Scholar
• Gan W Q, Man S F, Senthilselvan A, Sin D D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574–580
   PubMed Web of Science ®Google Scholar
• Broekhuizen R, Wouters E F, Creutzberg E C, Schols A M. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17–22
   PubMed Web of Science ®Google Scholar
• Sauleda J, Noguera A, Busquets X, Miralles C, Villaverde J M, Agusti A GN. Systemic inflammation during exacerbations of chronic obstructive pulmonary disease. Lack of effect of steroid treatment [abstract]. Eur Respir J 1999; 14: 359s
   Google Scholar
• Asin J, Maesen B LP, van den Bosch J MM, Schramel F MNH, van Grinsven S MGE, Gerritsen W BM, Haas F JLM. Serum interleukin-8, circulating cell adhesion molecules and hydrogen peroxide in exhaled air in patients with unstable chronic obstructive pulmonary disease during treatment with corticosteroids [abstract]. Eur Respir J 1998; 12: 193s
   PubMedGoogle Scholar
• Wedzicha J A, Seemungal T A, MacCallum P K, Paul E A, Donaldson G C, Bhowmik A, Jeffries D J, Meade T W. Acute exacerbations of chronic obstructive pulmonary disease accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84: 210–215
   PubMed Web of Science ®Google Scholar
• Spruit M A, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, Bouillon R, Decramer M. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003; 58: 752–756
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler D A, Jones P W, Wanner A, San P G, Zu Wallack R L, Menjoge S S, Serby C W, Witek T, Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–224
   PubMed Web of Science ®Google Scholar
• Vincken W, van Noord J A, Greefhorst A P, Bantje T A, Kesten S, Korducki L, Cornelissen P J. Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19: 209–216
   PubMed Web of Science ®Google Scholar
• Niewoehner D E, Rice K, Cote C, Paulson D, Cooper J A, Jr, Korducki L, Cassino C, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143: 317–326
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, Jones P, Price N, Gulsvik A, Anderson J, Maden C, Trial of Inhaled Steroids And long-acting beta2 agonists study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449–456
   PubMed Web of Science ®Google Scholar
• Calverley P M, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912–919
   PubMed Web of Science ®Google Scholar
• Sin D D, McAlister F A, Man S F, Anthonisen N R. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003; 290: 2301–2312
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, Connett J E, Kiley J P, Altose M D, Bailey W C, Buist A S, Conway W A, Jr, Enright P L, Kanner R E, O'Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497–1505
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, Connett J E, Murray R P. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675–679
   PubMed Web of Science ®Google Scholar
• Anthonisen N R, Skeans M A, Wise R A, Manfreda J, Kanner R E, Connett J E, Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233–239
   PubMed Web of Science ®Google Scholar
• Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005; 18: 75–81
   PubMed Web of Science ®Google Scholar
• Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 2004; 24: 206–210
   PubMed Web of Science ®Google Scholar
• Sutherland E R, Allmers H, Ayas N T, Venn A J, Martin R J. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58: 937–941
   PubMed Web of Science ®Google Scholar
• Decramer M, Celli B, Tashkin D P, Pauwels R A, Burkhart D, Cassino C, Kesten S. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT® trial. COPD 2004; 1: 303–312
   PubMedGoogle Scholar
• Donaldson G C, Wilkinson T M, Hurst J R, Perera W R, Wedzicha J A. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 446–452
   PubMed Web of Science ®Google Scholar
• Pitta F, Troosters T, Probst V S, Spruit M A, Decramer M, Gosselink R. Physical activity and hospitalization for exacerbation of COPD. Chest 2006; 129: 536–544
   PubMed Web of Science ®Google Scholar
• Cooper C B. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 2006; 119: 21–31, (10 Suppl 1)
   PubMed Web of Science ®Google Scholar
• Agusti A G, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347–360
   PubMed Web of Science ®Google Scholar
• Agusti A G. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 367–370
   PubMedGoogle Scholar
• Wouters E F. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 26–33
   PubMedGoogle Scholar
• Vernooy J H, Küçükaycan M, Jacobs J A, Chavannes N H, Buurman W A, Dentener M A, Wouters E F. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. Am J Respir Crit Care Med 2002; 166: 1218–1224
   PubMed Web of Science ®Google Scholar
• Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996; 154: 1055–1060, (4 Pt 1)
   PubMed Web of Science ®Google Scholar
• Praticò D, Basili S, Vieri M, Cordova C, Violi F, Fitzgerald G A. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am J Respir Crit Care Med 1998; 158: 1709–1714
   PubMed Web of Science ®Google Scholar
• Burnett D, Chamba A, Hill S L, Stockley R A. Neutrophils from subjects with chronic obstructive lung disease show enhanced chemotaxis and extracellular proteolysis. Lancet 1987; 2: 1043–1046
   PubMed Web of Science ®Google Scholar
• Noguera A, Batle S, Miralles C, Iglesias J, Busquets X, MacNee W, Agusti A G. Enhanced neutrophil response in chronic obstructive pulmonary disease. Thorax 2001; 56: 432–437
   PubMed Web of Science ®Google Scholar
• Noguera A, Busquets X, Sauleda J, Villaverde J M, MacNee W, Agusti A G. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1664–1668, (5 Pt 1)
   PubMed Web of Science ®Google Scholar
• Li Y P, Schwartz R J, Waddell I D, Holloway B R, Reid M B. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NF-kappaB activation in response to tumor necrosis factor alpha. FASEB J 1998; 12: 871–880
   PubMed Web of Science ®Google Scholar
• Agusti A G, Sauleda J, Miralles C, Gomez C, Togores B, Sala E, Batle S, Busquets X. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 485–489
   PubMed Web of Science ®Google Scholar
• Janssen S P, Gayan-Ramirez G, Van den Bergh A, Herijgers P, Maes K, Verbeken E, Decramer M. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005; 111: 996–1005
   PubMed Web of Science ®Google Scholar
• Booth F W, Gordon S E, Carlson C J, Hamilton M T. Waging war on modern chronic diseases: primary prevention through exercise biology. J Appl Physiol 2000; 88: 774–787
   PubMed Web of Science ®Google Scholar
• Pitta F, Troosters T, Spruit M A, Probst V S, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 972–977
   PubMed Web of Science ®Google Scholar
• Belza B, Steele B G, Hunziker J, Lakshminaryan S, Holt L, Buchner D M. Correlates of physical activity in chronic obstructive pulmonary disease. Nurs Res 2001; 50: 195–202
   PubMed Web of Science ®Google Scholar
• Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997; 10: 417–423
   PubMed Web of Science ®Google Scholar
• Marquis K, Debigaré R, Lacasse Y, LeBlanc P, Jobin J, Carrier G, Maltais F. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 809–813
   PubMed Web of Science ®Google Scholar
• Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, Garvey C, Goldstein R, Gosselink R, Lareau S, MacIntyre N, Maltais F, Morgan M, O'Donnell D, Prefault C, Reardon J, Rochester C, Schols A, Singh S, Troosters T, ATS/ERS Pulmonary Rehabilitation Writing Committee. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173: 1390–1413
   PubMed Web of Science ®Google Scholar
• Saey D, Debigare R, LeBlanc P, Mador M J, Cote C H, Jobin J, Maltais F. Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 425–430
   PubMed Web of Science ®Google Scholar
• Sala E, Roca J, Marrades R M, Alonso J, Gonzalez de Suso J M, Moreno A, Barberá JÁ, Nadal J, do Jover L, Rodriguez-Roísin R, Wagner P D. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 1726–1734
   PubMed Web of Science ®Google Scholar
• Whittom F, Jobin J, Simard P M, LeBlanc P, Simard C, Bernard S, Belleau R, Maltais F. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc 1998; 30: 1467–1474
   PubMed Web of Science ®Google Scholar
• Maltais F, LeBlanc P, Whittom F, Simard C, Marquis K, Bélanger M, Breton M J, Jobin J. Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD. Thorax 2000; 55: 848–853
   PubMed Web of Science ®Google Scholar
• Rabinovich R A, Ardite E, Troosters T, Carbó N, Alonso J, Gonzalez de Suso J M, Vilaró J, Barberà J A, Polo M F, Argilés J M, Fernandez-Checa J C, Roca J. Reduced muscle redox capacity after endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1114–1118
   PubMed Web of Science ®Google Scholar
• Rabinovich R A, Ardite E, Mayer A M, Polo M F, Vilaró J, Argilés J M, Roca J. Training depletes muscle glutathione in patients with chronic obstructive pulmonary disease and low body mass index. Respiration 2006; 73(6)757–761
   PubMed Web of Science ®Google Scholar
• Rabinovich R A, Bastos R, Ardite E, Llinàs L, Orozco-Levi M, Gea J, Vilaró J, Barberà J A, Rodriquez-Roísin R, Fernandez-Checa J C, Roca J. Mitochondrial dysfunction in COPD patients with low body mass index. Eur Respir J 2007; 29: 643–650
   PubMed Web of Science ®Google Scholar
• Smorawiński J, Nazar K, Kaciuba-Uscilko H, Kamińska E, Cybulski G, Kodrzycka A, Bicz J E. Greenleaf Effects of 3-day bed rest on physiological responses to graded exercise in athletes and sedentary men. J Appl Physiol 2001; 91: 249–257
   PubMed Web of Science ®Google Scholar
• Decramer M, Lacquet L M, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150: 11–16
   PubMed Web of Science ®Google Scholar
• Koechlin C, Couillard A, Simar D, Cristol J P, Bellet H, Hayot M, Prefaut C. Does oxidative stress alter quadriceps endurance in chronic obstructive pulmonary disease?. Am J Respir Crit Care Med 2004; 169: 1022–1027
   PubMed Web of Science ®Google Scholar
• Powers S K, Kavazis A N, Deruisseau K C. Mechanisms of disuse muscle atrophy: role of oxidative stress. Am J Physiol Regul Integr Comp Physiol 2005; 288: R337–R344
   PubMed Web of Science ®Google Scholar
• Bruunsgaard H. Physical activity and modulation of systemic low-level inflammation. J Leukoc Biol 2005; 78: 819–835
   PubMed Web of Science ®Google Scholar
• Van Vliet M, Spruit M A, Verleden G, Kasran A, Van Herck E, Pitta F, Bouillon R, Decramer M. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 1105–1111
   PubMed Web of Science ®Google Scholar
• Jones R CM, Hyland M E, Hanney K, Erwin J. A qualitative study of compliance with medication and lifestyle modification in chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2004; 13: 149–154
   PubMedGoogle Scholar
• De Peuter S, Van Diest I, Lemaigre V, Verleden G, Demedts M, Van den Bergh O. Dyspnea: the role of psychological processes. Clin Psychol Rev 2004; 24: 557–581
   PubMed Web of Science ®Google Scholar
• NIH Consensus development program. Osteoporosis prevention, diagnosis and therapy. NIH consensus statement, Washington, DC 2000; 17: 1–45
   Google Scholar
• Lorentzon M, Mellström D, Haug E, Ohlsson C. Smoking is associated with lower bone mineral density and reduced cortical thickness in young men. J Clin Endocrinol Metab 2007; 92: 497–503
   PubMed Web of Science ®Google Scholar
• Rochira V, Balestrieri A, Madeo B, Birilli L, Granata A R, Carani C. Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho)physiology. Eur J Endocrinol 2006; 154: 175–185
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Longitudinal deteriorations in patient reported outcomes in patients with COPD. Respir Med 2007; 101: 146–153
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Voduc N, Fitzpatrick M, Webb K A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 86–94
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Sciurba F, Celli B, Mahler D A, Webb K A, Kalberg C J, Knobil K. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130: 647–656
   PubMed Web of Science ®Google Scholar
• Couillard A, Maltais F, Saey D, Debigaré R, Michaud A, Koechlin C, LeBlanc P, Préfaut C. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167: 1664–1669
   PubMed Web of Science ®Google Scholar
• Mador M J, Kufel T J, Pineda L A, Steinwald A, Aggarwal A, Upadhyay A M, Khan M A. Effect of pulmonary rehabilitation on quadriceps fatiguability during exercise. Am J Respir Crit Care Med 2001; 163: 930–935
   PubMed Web of Science ®Google Scholar
• Casaburi R, Porszasz J, Burns M R, Carithers E R, Chang R S, Cooper C B. Physiologic benefits of exercise training in rehabilitation of patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155: 1541–1551
   PubMed Web of Science ®Google Scholar
• Porszasz J, Emtner M, Goto S, Somfay A, Whipp B J, Casaburi R. Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest 2005; 128: 2025–2034
   PubMed Web of Science ®Google Scholar
• Somfay A, Porszasz J, Lee S M, Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patients. Eur Respir J 2001; 18: 77–84
   PubMed Web of Science ®Google Scholar
• Probst V S, Heyvaert H, Coosemans I, Pitta F, Spruit M A, Troosters T, Gosselink R, Decramer M. Effects of a rollator on exercise capacity, gas exchange and ventilation in COPD patients [abstract]. Am J Respir Crit Care Med 2003; 167: A669
   Google Scholar
• Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood D E, National Emphysema Treatment Trial Research Group. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348: 2059–2073
   PubMed Web of Science ®Google Scholar
• Casaburi R, Kukafka D, Cooper C B, Witek T J, Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809–817
   PubMed Web of Science ®Google Scholar
• Peters M M, Webb K A, O'Donnell D E. Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD. Thorax 2006; 61: 559–567
   PubMed Web of Science ®Google Scholar
• Ram F S, Wedzicha J A. Ambulatory oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002, (2):CD000238
   Google Scholar
• Kannus P, Palvanen M, Niemi S, Parkkari J, Järvinen M, Vuori I. Osteoporotic fractures of the proximal humerus in elderly Finnish persons: sharp increase in 1970-1998 and alarming projections for the new millennium. Acta Orthop Scand 2000; 71: 465–470
   PubMed Web of Science ®Google Scholar
• Wehren L E. The epidemiology of osteoporosis and fractures in geriatric medicine. Clin Geriatr Med 2003; 19: 245–258
   PubMed Web of Science ®Google Scholar
• O'Neill T W, Felsenberg D, Varlow J, Cooper C, Kanis J A, Silman A J. The prevalence of vertebral deformity in european men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996; 11: 1010–1018
   PubMed Web of Science ®Google Scholar
• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. National Institutes of Health, Accessed 1 December 2006, NIH Consensus Statement Online
   Google Scholar
• Consensus development conference. Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646–650
   PubMed Web of Science ®Google Scholar
• World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. 843. World Health Organization, GenevaSwitzerland 1994, WHO Technical Report Series
   Google Scholar
• Rosen C J, Brown S A. A rational approach to evidence gaps in the management of osteoporosis. Am J Med 2005; 118: 1183–1189
   PubMed Web of Science ®Google Scholar
• Leech J A, Dulberg C, Kellie S, Pattee L, Gay J. Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis 1990; 141: 68–71
   PubMed Web of Science ®Google Scholar
• Schlaich C, Minne H W, Bruckner T, Wagner G, Gebest H J, Grunze M, Ziegler R, Leidig-Bruckner G. Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos Int 1998; 8: 261–267
   PubMed Web of Science ®Google Scholar
• Culham E G, Jimenez H A, King C E. Thoracic kyphosis, rib mobility, and lung volumes in normal women and women with osteoporosis. Spine 1994; 19: 1250–1255
   PubMed Web of Science ®Google Scholar
• Moffett S P, Zmuda J M, Oakley J I, Beck T J, Cauley J A, Stone K L, Lui L Y, Ensrud K E, Hillier T A, Hochberg M C, Morin P, Peltz G, Greene D, Cummings S R. Tumor necrosis factor-alpha polymorphism, bone strength phenotypes, and the risk of fracture in older women. J Clin Endocrinol Metab 2005; 90: 3491–3497
   PubMed Web of Science ®Google Scholar
• Gourlay M, Richy F, Reginster J Y. Strategies for the prevention of hip fracture. Am J Med 2003; 115: 309–317
   PubMed Web of Science ®Google Scholar
• Filley G F, Beckwitt H J, Reeves J T, Mitchell R S. Chronic obstructive bronchopulmonary disease. II. Oxygen transport in two clinical types. Am J Med 1968; 44: 26–38
   Google Scholar
• Vandenbergh E, Van de Woestijne K P, Gyselen A. Weight changes in the terminal stages of chronic obstructive pulmonary disease. Relation to respiratory function and prognosis. Am Rev Respir Dis 1967; 95: 556–566
   PubMed Web of Science ®Google Scholar
• Braun S R, Keim N L, Dixon R M, Glagnaz P, Anderegg A, Shrago E S. The prevalence and determinants of nutritional changes in chronic obstructive pulmonary disease. Chest 1984; 86: 558–563
   PubMed Web of Science ®Google Scholar
• Mitchell R S, Filley G F. Chronic obstructive bronchopulmonary disease. I. Clinical features. Am Rev Respir Dis 1964; 89: 360–371
   PubMed Web of Science ®Google Scholar
• Hunter A M, Carey M A, Larsh H W. The nutritional status of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1981; 124: 376–381
   PubMed Web of Science ®Google Scholar
• Wilson D O, Rogers R M, Wright E C, Anthonisen N R. Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 1989; 139: 1435–1438
   Google Scholar
• Sahebjami H, Doers J T, Render M L, Bond T L. Anthropometric and pulmonary function test profiles of outpatients with stable chronic obstructive pulmonary disease. Am J Med 1993; 94: 469–474
   PubMed Web of Science ®Google Scholar
• Schols A M, Soeters P B, Dingemans A M, Mostert R, Frantzen P J, Wouters E F. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151–1156
   PubMed Web of Science ®Google Scholar
• Openbrier D R, Irwin M M, Rogers R M, Gottlieb G P, Dauber J H, Van Thiel D H, Pennock B E. Nutritional status and lung function in patients with emphysema and chronic bronchitis. Chest 1983; 83: 17–22
   PubMed Web of Science ®Google Scholar
• Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard B G, Andersen T, Sørensen T I, Lange P. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006; 173(1)79–83
   PubMed Web of Science ®Google Scholar
• Vermeeren M A, Creutzberg E C, Schols A M, Postma D S, Pieters W R, Roldaan A C, Wouters E F, COSMIC Study Group. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med 2006; 100: 1349–1355
   PubMed Web of Science ®Google Scholar
• Schols A M, Broekhuizen R, Weling-Scheepers C A, Wouters E F. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005; 82: 53–59
   PubMed Web of Science ®Google Scholar
• Engelen M P, Schols A M, Does J D, Wouters E F. Skeletal muscle weakness is associated with wasting of extremity fat-free mass but not with airflow obstruction in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 2000; 71: 733–738
   PubMed Web of Science ®Google Scholar
• Creutzberg E C, Schols A M, Bothmer-Quaedvlieg F C, Wouters E F. Prevalence of an elevated resting energy expenditure in patients with chronic obstructive pulmonary disease in relation to body composition and lung function. Eur J Clin Nutr 1998; 52: 396–401
   PubMed Web of Science ®Google Scholar
• Hugli O, Schutz Y, Fitting J W. The cost of breathing in stable chronic obstructive pulmonary disease. Clin Sci (Lond) 1995; 89: 625–632
   PubMed Web of Science ®Google Scholar
• Baarends E M, Schols A M, Westerterp K R, Wouters E F. Total daily energy expenditure relative to resting energy expenditure in clinically stable patients with COPD. Thorax 1997; 52: 780–785
   PubMed Web of Science ®Google Scholar
• Baarends E M, Schols A M, Pannemans D L, Westerterp K R, Wouters E F. Total free living energy expenditure in patients with severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 155: 549–554
   PubMed Web of Science ®Google Scholar
• Vermeeren M A, Wouters E F, Geraerts-Keeris A J, Schols A M. Nutritional support in patients with chronic obstructive pulmonary disease during hospitalization for an acute exacerbation; a randomized controlled feasibility trial. Clin Nutr 2004; 23: 1184–1192
   PubMed Web of Science ®Google Scholar
• Creutzberg E C, Wouters E F, Vanderhoven-Augustin I M, Dentener M A, Schols A M. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162: 1239–1245, (4 Pt 1)
   PubMed Web of Science ®Google Scholar
• Karajgi B, Rifkin A, Doddi S, Kolli R. The prevalence of anxiety disorders in patients with chronic obstructive pulmonary disease. Am J Psychiatry 1990; 147: 200–201
   PubMed Web of Science ®Google Scholar
• Moore M C, Zebb B J. The catastrophic misinterpretation of physiological distress. Behav Res Ther 1999; 37: 1105–1118
   PubMed Web of Science ®Google Scholar
• Yellowlees P M, Haynes S, Potts N, Ruffin R E. Psychiatric morbidity in patients with life-threatening asthma: initial report of a controlled study. Med J Aust 1988; 149: 246–249
   PubMed Web of Science ®Google Scholar
• Borak J, Chodosowska E, Matuszewski A, Zielinski J. Emotional status does not alter exercise tolerance in patients with chronic obstructive pulmonary disease. Eur Respir J 1998; 12: 370–373
   PubMed Web of Science ®Google Scholar
• Engström C P, Persson L O, Larsson S, Rydén A, Sullivan M. Functional status and well being in chronic obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and comparative study. Thorax 1996; 51: 825–830
   PubMed Web of Science ®Google Scholar
• Kim H F, Kunik M E, Molinari V A, Hillman S L, Lalani S, Orengo C A, Petersen N J, Nahas Z, Goodnight-White S. Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics 2000; 41: 465–471
   PubMed Web of Science ®Google Scholar
• Prigatano G P, Wright E C, Levin D. Quality of life and its predictors in patients with mild hypoxemia and chronic obstructive pulmonary disease. Arch Intern Med 1984; 144: 1613–1619
   PubMed Web of Science ®Google Scholar
• Withers N J, Rudkin S T, White R J. Anxiety and depression in severe chronic obstructive pulmonary disease: the effects of pulmonary rehabilitation. J Cardiopulm Rehabil 1999; 19: 362–365
   PubMedGoogle Scholar
• Yohannes A M, Baldwin R C, Connolly M J. Depression and anxiety in elderly outpatients with chronic obstructive pulmonary disease: prevalence, and validation of the BASDEC screening questionnaire. Int J Geriatr Psychiatry 2000; 15: 1090–1096
   PubMed Web of Science ®Google Scholar
• Kvaal K, Macijauskiene J, Engedal K, Laake K. High prevalence of anxiety symptoms in hospitalized geriatric patients. Int J Geriatr Psychiatry 2001; 16: 690–693
   PubMed Web of Science ®Google Scholar
• van Manen J G, Bindels P J, Dekker F WI, Jzermans C J, van der Zee J S, Schadé E. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002; 57: 412–416
   PubMed Web of Science ®Google Scholar
• van Ede L, Yzermans C J, Brouwer H J. Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. Thorax 1999; 54: 688–692
   PubMed Web of Science ®Google Scholar
• Felker B, Katon W, Hedrick S C, Rasmussen J, McKnight K, McDonnell M B, Fihn S D. The association between depressive symptoms and health status in patients with chronic pulmonary disease. Gen Hosp Psychiatry 2001; 23: 56–61
   PubMed Web of Science ®Google Scholar
• Cully J A, Graham D P, Stanley M A, Ferguson C J, Sharafkhaneh A, Souchek J, Kunik M E. Quality of life in patients with chronic obstructive pulmonary disease and comorbid anxiety or depression. Psychosomatics 2006; 47: 312–319
   PubMed Web of Science ®Google Scholar
• Beck J G, Scott S K, Teague R B, Perez F I, Brown G A. Correlates of daily impairment in COPD. Rehabil Psychol 1988; 33: 77–84
   Web of Science ®Google Scholar
• Dahlen I, Janson C. Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Chest 2002; 122: 1633–1637
   PubMed Web of Science ®Google Scholar
• Almagro P, Calbo E, Ochoa de Echagüen A, Barreiro B, Quintana S, Heredia J L, Garau J. Mortality after hospitalization for COPD. Chest 2002; 121: 1441–1448
   PubMed Web of Science ®Google Scholar
• Di Marco F, Verga M, Reggente M, Maria Casanova F, Santus P, Blasi F, Allegra L, Centanni S. Anxiety and depression in COPD patients: The roles of gender and disease severity. Respir Med 2006; 100: 1767–1774
   PubMed Web of Science ®Google Scholar
• de Torres J P, Casanova C, Hernández C, Abreu J, Aguirre-Jaime A, Celli B R. Gender and COPD in patients attending a pulmonary clinic. Chest 2005; 128: 2012–2016
   PubMed Web of Science ®Google Scholar
• de Torres J P, Casanova C, Hernández C, Abreu J, Montejo de Garcini A, Aguirre-Jaime A, Celli B R. Gender associated differences in determinants of quality of life in patients with COPD: a case series study. Health Qual Life Outcomes 2006; 4: 72
   PubMed Web of Science ®Google Scholar
• Thomsen D K, Mehlsen M Y, Viidik A, Sommerlund B, Zachariae R. Age and gender differences in negative affect. Is there a role for emotion regulation? Personality Individ Diff 2005; 38: 1935–1946
   Web of Science ®Google Scholar
• Nolen-Hoeksema S, Larson J, Grayson C. Explaining the gender difference in depressive symptoms. J Pers Soc Psychol 1999; 77: 1061–1072
   PubMed Web of Science ®Google Scholar
• Musselman D L, Miller A H, Porter M R, Manatunga A, Gao F, Penna S, Pearce B D, Landry J, Glover S, McDaniel J S, Nemeroff C B. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001; 158: 1252–1257
   PubMed Web of Science ®Google Scholar
• Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999; 461: 25–46
   PubMed Web of Science ®Google Scholar
• Raison C L, Demetrashvili M, Capuron L, Miller A H. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005; 19: 105–123
   PubMed Web of Science ®Google Scholar
• Berkenbosch F, van Oers J, del Rey A, Tilders F, Besedovsky H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 1987; 238: 524–526
   PubMed Web of Science ®Google Scholar
• Borson S, Claypoole K, McDonald G J. Depression and chronic obstructive pulmonary disease: treatment trials. Semin Clin Neuropsychiatry 1998; 3: 115–130
   PubMedGoogle Scholar
• Sanders S K, Morzorati S L, Shekhar A. Priming of experimental anxiety by repeated subthreshold GABA blockade in the rat amygdala. Brain Res 1995; 699: 250–259
   PubMed Web of Science ®Google Scholar
• Shekhar A, Sajdyk T J, Gehlert D R, Rainnie D G. The amygdala, panic disorder, and cardiovascular responses. Ann N Y Acad Sci 2003; 985: 308–325
   PubMed Web of Science ®Google Scholar
• Porzelius J, Vest M, Nochomovitz M. Respiratory function, cognitions, and panic in chronic obstructive pulmonary patients. Behav Res Ther 1992; 30: 75–77
   PubMed Web of Science ®Google Scholar
• Breslau N, Klein D F. Smoking and panic attacks: an epidemiologic investigation. Arch Gen Psychiatry 1999; 56: 1141–1147
   PubMed Web of Science ®Google Scholar
• Kendler K S, Neale M C, MacLean C J, Heath A C, Eaves L J, Kessler R C. Smoking and major depression. A causal analysis. Arch Gen Psychiatry 1993; 50: 36–43
   PubMed Web of Science ®Google Scholar
• Hanania N A, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: 834–843
   PubMed Web of Science ®Google Scholar
• Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144–149
   PubMed Web of Science ®Google Scholar
• Griffiths T L, Burr M L, Campbell I A, Lewis-Jenkins V, Mullins J, Shiels K, Tumer-Lawlor P J, Payne N, Newcombe R G, Ionescu A A, Thomas J, Tunbridge J. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000; 355: 362–368
   PubMed Web of Science ®Google Scholar
• Kayahan B, Karapolat H, Atýntoprak E, Atasever A, Oztürk O. Psychological outcomes of an outpatient pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease. Respir Med 2006; 100: 1050–1057
   PubMed Web of Science ®Google Scholar
• Eaton T, Garrett J E, Young P, Fergusson W, Kolbe J, Rudkin S, Whyte K. Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. Eur Respir J 2002; 20: 306–312
   PubMed Web of Science ®Google Scholar
• Lorig K R, Sobel D S, Ritter P L, Laurent D, Hobbs M. Effect of a self-management program on patients with chronic disease. Eff Clin Pract 2001; 4: 256–262
   PubMedGoogle Scholar
• Harte J L, Eifert G H, Smith R. The effects of running and meditation on beta-endorphin, corticotropin-releasing hormone and cortisol in plasma, and on mood. Biol Psychol 1995; 40: 251–265
   PubMed Web of Science ®Google Scholar
• Nabkasorn C, Miyai N, Sootmongkol A, Junprasert S, Yamamoto H, Arita M, Miyashita K. Effects of physical exercise on depression, neuroendocrine stress hormones and physiological fitness in adolescent females with depressive symptoms. Eur J Public Health 2006; 16: 179–184
   PubMed Web of Science ®Google Scholar
• Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med 2000; 109: 207–212
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupré A, Bégin R, Renzi P, Nault D, Borycki E, Schwartzman K, Singh R, Collet J P. Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santé du Québec. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003; 163: 585–591
   PubMed Web of Science ®Google Scholar
• Janowsky D S, Overstreet D H, Nurnberger J I, Jr. Is cholinergic sensitivity a genetic marker for the affective disorders?. Am J Med Genet 1994; 54: 335–344
   PubMed Web of Science ®Google Scholar
• Mannino D M, Ford E S, Redd S C. Obstructive and restrictive lung disease and functional limitation: data from the Third National Health and Nutrition Examination. J Intern Med 2003; 254: 540–547
   PubMed Web of Science ®Google Scholar
• Andreas S, Anker S D, Scanlon P D, Somers V K. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 2005; 128: 3618–3624
   PubMed Web of Science ®Google Scholar
• Mannino D M, Homa D M, Akinbami L J, Ford E S, Redd S C. Chronic obstructive pulmonary disease surveillance—United States, 1971-2000. Respir Care 2002; 47: 1184–1199
   PubMedGoogle Scholar
• Mannino D M, Brown C, Giovino G A. Obstructive lung disease deaths in the United States from 1979 through 1993. An analysis using multiple-cause mortality data. Am J Respir Crit Care Med 1997; 156: 814–818, (3 Pt 1)
   PubMed Web of Science ®Google Scholar
• Camilli A E, Robbins D R, Lebowitz M D. Death certificate reporting of confirmed airways obstructive disease. Am J Epidemiol 1991; 133: 795–800
   PubMed Web of Science ®Google Scholar
• Vilkman S, Keistinen T, Tuuponen T, Kivelä S L. Survival and cause of death among elderly chronic obstructive pulmonary disease patients after first admission to hospital. Respiration 1997; 64: 281–284
   PubMed Web of Science ®Google Scholar
• Zielinski J, MacNee W, Wedzicha J, Ambrosino N, Braghiroli A, Dolensky J, Howard P, Gorzelak K, Lahdensuo A, Strom K, Tobiasz M, Weitzenblum E. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis 1997; 52: 43–47
   PubMedGoogle Scholar
• Holguin F, Folch E, Redd S C, Mannino D M. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128: 2005–2011
   PubMed Web of Science ®Google Scholar
• Mannino D M, Doherty D E, Sonia B A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006; 100: 115–122
   PubMed Web of Science ®Google Scholar
• Mannino D M, Buist A S, Petty T L, Enright P L, Redd S C. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58: 388–393
   PubMed Web of Science ®Google Scholar
• Calverley P M, Anderson J A, Celli B, Ferguson G T, Jenkins C, Jones P W, Yates J C, Vestbo J, TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775–789
   PubMed Web of Science ®Google Scholar
• Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004; 328: 1519
   PubMed Web of Science ®Google Scholar
• The nocturnal oxygen therapy trial–NOTT. Is 12-hour oxygen as effective as 24-hour oxygen in advanced chronic obstructive pulmonary disease with hypoxemia? (The nocturnal oxygen therapy trial–NOTT). Chest 1980; 78: 419–420
   PubMed Web of Science ®Google Scholar
• Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681–686
   PubMed Web of Science ®Google Scholar
• Piccioni P, Caria E, Bignamini E, Forconi G, Nebiolo F, Arossa W, Bugiani M. Predictors of survival in a group of patients with chronic airflow obstruction. J Clin Epidemiol 1998; 51: 547–555
   PubMed Web of Science ®Google Scholar
• Kinnunen T, Säynäjäkangas O, Keistinen T. The COPD-induced hospitalization burden from first admission to death. Respir Med 2007; 101: 294–299
   PubMed Web of Science ®Google Scholar
• Cote C G, Celli B R. Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005; 26: 630–636
   PubMed Web of Science ®Google Scholar
• Wilt T J, Niewoehner D, Kim C, Kane R L, Linabery A, Tacklind J, Macdonald R, Rutks I. Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Evid Rep Technol Assess (Summ) 2005; 121: 1–7
   PubMedGoogle Scholar
• Bednarek M, Gorecka D, Wielgomas J, Czajkowska-Malinowska M, Regula J, Mieszko-Filipczyk G, Jasionowicz M, Bijata-Bronisz R, Lempicka-Jastrzebska M, Czajkowski M, Przybylski G, Zielinski J. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006; 61: 869–873
   PubMed Web of Science ®Google Scholar
• Tashkin D P. The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding. Am J Med 2006; 119: 63–72, (10 Suppl 1)
   PubMedGoogle Scholar
• Huiart L, Ernst P, Ranouil X, Suissa S. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 250: 634–639
   Google Scholar
• Papi A, Bellettato C M, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri L M, Johnston S L. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006; 173: 1114–1121
   PubMed Web of Science ®Google Scholar
• Oudijk E J, Gerritsen W B, Nijhuis E H, Kanters D, Maesen B L, Lammers J W, Koenderman L. Expression of priming-associated cellular markers on neutrophils during an exacerbation of COPD. Respir Med 2006; 100: 1791–1799
   PubMed Web of Science ®Google Scholar
• Tug T, Karatas F, Terzi S M. Antioxidant vitamins (A, C and E) and malondialdehyde levels in acute exacerbation and stable periods of patients with chronic obstructive pulmonary disease. Clin Invest Med 2004; 27: 123–128
   PubMed Web of Science ®Google Scholar
• Sethi S, Wrona C, Veeramachaneni S, Eschbeger K, Muphy T F. Changes in serum C-reactive protein (CRP) with onset and resolution of exacerbations of COPD and relationship with etiology. [Abstract] Proc Am Thorac Soc 2006; 3: A271
   Google Scholar
• Scanlon P D, Connett J E, Wise R A, Tashkin D P, Madhok T, Skeans M, Carpenter P C, Bailey W C, Buist A S, Eichenhorn M, Kanner R E, Weinmann G, Lung Health Study Research Group. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med 2004; 170: 1302–1309
   PubMed Web of Science ®Google Scholar
• Burge P S, Calverley P M, Jones P W, Spencer S, Anderson J A. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003; 58: 654–658
   PubMed Web of Science ®Google Scholar
• Celli B R, MacNee W, committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–946
   PubMed Web of Science ®Google Scholar
• Burge S, Wedzicha J A. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003; 41: S46–S53
   PubMedGoogle Scholar
• Niewoehner D E. The impact of severe exacerbations on quality of life and the clinical course of chronic obstructive pulmonary disease. Am J Med 2006; 119: 38–45, (10 Suppl 1)
   PubMed Web of Science ®Google Scholar
• Cooper C B, Tashkin D P. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. BMJ 2005; 330: 640–644
   PubMed Web of Science ®Google Scholar
• Rennard S I, Calverley P. Rescue! Therapy and the paradox of the Barcalounger. Eur Respir J 2003; 21: 916–917
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Mulley B A, Peake M D. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ 1988; 297: 1506–1510
   PubMed Web of Science ®Google Scholar
• Belman M J, Botnick W C, Shin J W. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967–975
   PubMed Web of Science ®Google Scholar
• Newton M F, O'Donnell D E, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121: 1042–1050
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Lam M IU, Webb K A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158: 1557–1565
   PubMed Web of Science ®Google Scholar
• Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–1748
   PubMed Web of Science ®Google Scholar
• O'Donnell D E, Flüge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in patients with COPD. Eur Respir J 2004; 23: 832–840
   PubMed Web of Science ®Google Scholar
• Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba F C, Richter K, Kesten S, O'Donnell D. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168–1178
   PubMed Web of Science ®Google Scholar
• Palange P, Valli G, Onorati P, Antonucci R, Paoletti P, Rosato A, Manfredi F, Serra P. Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients. J Appl Physiol 2004; 97: 1637–1642
   PubMed Web of Science ®Google Scholar
• Pecchiari M, Pelucchi A, D'Angelo E, Foresi A, Milic-Emili J, D'Angelo E. Effect of heliox breathing on dynamic hyperinflation in COPD patients. Chest 2004; 125: 2075–2082
   PubMed Web of Science ®Google Scholar
• Hopkinson N S, Toma T P, Hansell D M, Goldstraw P, Moxham J, Geddes D M, Polkey M I. Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med 2005; 171: 453–460
   PubMed Web of Science ®Google Scholar
• Koyama S, Rennard S I, Robbins R A. Acetylcholine stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Physiol 1992; 262: L466–L471, (4 Pt 1)
   PubMed Web of Science ®Google Scholar
• Sato E, Koyama S, Okubo Y, Kubo K, Sekiguchi M. Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. Am J Physiol 1998; 274: 970–979, (6 Pt 1)
   PubMed Web of Science ®Google Scholar
• Buhling F, Lieder N, Reisenauer A, Welte T. Anti-inflammatory function of tiotropium mediated by suppression of acetylcholine-induced release of chemotactic activity. [Abstract] Eur Respir J 2004; 24: 318s
   Google Scholar
• Fukuchi K, Zushi H, Kikuchi Y, Hase M, Yasue T, Kishi T. Involvement of muscarinic receptor activation in cigarette smoke induced pulmonary inflammation in mice. [Abstract] Proc Am Thorac Soc 2005; 2: A142
   Google Scholar
• Lipworth B J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005; 365: 167–175
   PubMed Web of Science ®Google Scholar
• Gamble E, Grootendorst D C, Brightling C E, Troy S, Qiu Y, Zhu J, Parker D, Matin D, Majumdar S, Vignola A M, Kroegel C, Morell F, Hansel T T, Rennard S I, Compton C, Amit O, Tat T, Edelson J, Pavord I D, Rabe K F, Barnes N C, Jeffery P K. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 976–982
   PubMed Web of Science ®Google Scholar
• Martorana P A, Beume R, Lucattelli M, Wollin L, Lungarella G. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005; 172: 848–853
   PubMed Web of Science ®Google Scholar
• Hanania N A, Ambrosino N, Calverley P, Cazzola M, Donner C F, Make B. Treatments for COPD. Respir Med 2005; 99(Suppl B)S28–S40
   PubMed Web of Science ®Google Scholar
• Foglio K, Carone M, Pagani M, Bianchi L, Jones P W, Ambrosino N. Physiological and symptom determinants of exercise performance in patients with chronic airway obstruction. Respir Med 2000; 94: 256–263
   PubMed Web of Science ®Google Scholar
• Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Exercise capacity deterioration in patients with COPD: longitudinal evaluation over 5 years. Chest 2005; 128: 62–69
   PubMed Web of Science ®Google Scholar
• Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood J E. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002; 346: 793–801
   PubMed Web of Science ®Google Scholar
• Manini T M, Everhart J E, Patel K V, Schoeller D A, Colbert L H, Visser M, Tylavsky F, Bauer D C, Goodpaster B H, Harris T B. Daily activity energy expenditure and mortality among older adults. JAMA 2006; 296: 171–179
   PubMed Web of Science ®Google Scholar
• Barr R G, Bourbeau J, Camargo C A, Ram F S. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006; 61: 854–862
   PubMed Web of Science ®Google Scholar
• Alsaeedi A, Sin D D, McAlister F A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59–65
   PubMed Web of Science ®Google Scholar
• Donaldson G C, Seemungal T AR, Bhowmik A, Wedzicha J A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–852
   PubMed Web of Science ®Google Scholar